Somebody else pays first: management describes counterparties putting their own money down ahead of delivery
The model's full reasoning — Q1 2018 call → NOWe need to determine if management describes counterparties putting their own money or resources at risk before receiving what they pay for, as a real current phenomenon. The transcript mentions various things: customers buying instruments, consumables, etc. But does it mention prepayments, deposits, milestone payments? There is mention of "milestone payments associated with our recently announced oncology collaborations" in guidance. Also "Milestone payments associated with our recently announced oncology collaborations. These will be included in sequencing and other revenue." That suggests that there are milestone payments from partners (Loxo, BMS) that are part of revenue. But are these payments for something not yet delivered? Milestone payments in pharma collaborations are typically payments tied to achieving certain development or regulatory milestones, not necessarily prepayments for delivery. They are payments for achieving milestones, which is a form of payment for work done or progress. But the question is about counterparties putting money at risk before receiving what they pay for. Milestone payments are often paid upon achievement of a milestone, which is after some work is done. Not necessarily an advance. Also, the transcript says "we are planning some incremental R&D and commercial projects to capitalize on the momentum" and "we expect to see additional consumables and instruments sales as a result of these collaborations" but that's future. Look for any mention of deposits, prepayments, advance payments, customers funding capacity, etc. The transcript does not mention customers paying in advance. It mentions "stocking order" in Q4 for NovaSeq consumables, but that's a large order, not necessarily prepayment. It says "Excluding the $19 million stocking order in the fourth quarter, NovaSeq consumables grew approximately 60% sequentially" - that's just a large order, not prepayment. There is no mention of customers depositing money, reserving capacity, or funding the company. The only thing close is "milestone payments" but those are likely tied to achievements, not advance commitments. Also, the company's business model is selling instruments and consumables, typically paid on delivery or standard terms. No mention of advance payments. Thus, answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| PDS | Precision Drilling Corporation | Q1 2024 | 2024-04-25 | B |
| NBTX | Nanobiotix S.A. | Q2 2023 | 2023-09-27 | D |
| BLZE | Backblaze, Inc. | Q3 2022 | 2022-11-11 | D |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| EEX | Emerald Holding, Inc. | Q2 2021 | 2021-08-01 | C+ |
| SRDX | Surmodics, Inc. | Q3 2018 | 2018-08-06 | A |
| ROP | Roper Technologies, Inc. | Q2 2018 | 2018-07-26 | A |
| CPK | Chesapeake Utilities Corporation | Q3 2017 | 2017-11-10 | A |
| WYY | WidePoint Corporation | Q3 2016 | 2016-11-09 | D |
SYM · Q3 2022 → YESThe question is: Does management describe that the people on the OTHER SIDE of the company's business are now PUTTING THEIR OWN MONEY OR RESOURCES AT RISK BEFORE they receive what they are paying for ...YES The transcript shows management describing real advance commitments from customers: the $11.3 billion backlog (more than doubled), strong deferred revenue on the balance sheet representing a "very significant cost float," and contracts that lock in commitments with restricted changes. Revenue is recognized on a percentage-of-completion basis during deployment, meaning payments 18 months ahead of acceptance. This is framed as an active benefit enabling confident scaling, not a routine or historical norm. They also note improved supplier terms, but the customer-side pre-funding via deferred revenue and backlog is explicitly highlighted as occurring now. This meets the criteria for counterparties committing capital ahead of delivery.
EVGO · Q2 2022 → YESThe question is: Does management describe that the people on the OTHER SIDE of the company's business are now PUTTING THEIR OWN MONEY OR RESOURCES AT RISK BEFORE they receive what they are paying for ...YES The transcript shows management describing the eXtend model with Pilot and GM where the customer (Pilot/GM) incurs the upfront capital expenditures for the charging infrastructure, while EVgo receives ongoing revenues from operations, maintenance, and services. This is presented as an actual, current business arrangement that provides EVgo with immediate cash flow and contracted revenues, not as a future hope or industry norm. Cathy Zoi notes the agreement exceeds IRR hurdles and provides near-term revenue, and Olga Shevorenkova explains the customer funds the build-out, enabling EVgo to generate margin as developer and operator.
BLZE · Q3 2022 → YESThe question is: Does management describe that the people on the OTHER SIDE of the company's business are now PUTTING THEIR OWN MONEY OR RESOURCES AT RISK BEFORE they receive what they are paying for ...YES The transcript shows management describing B2 Reserve as a capacity-based pricing program that includes premium support and free data migration, with revenue ramping in Q3. Frank notes B2 Reserve contracts are "effectively committed contracts," and Gleb calls them "committed contracts" in response to an investor question. This is presented as occurring now, with "initial ramp in demand" and "revenue increasing each month of Q3," not as a future plan or industry norm. The capacity-reservation aspect aligns with the described phenomenon of counterparties committing capital in advance.